Thursday, November 26

BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia

 BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia

BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia

Shots:

  • BioMarin has submitted an NDA to the US FDA for vosoritide to treat children with achondroplasia
  • The company also reported that EMA has begun validation of MAA for the therapy on 13 Aug, 2020
  • Vosoritide is an investigational, once-daily injection analog of C-type Natriuretic Peptide (CNP) and is potentially the first treatment for achondroplasia in the US

Click here ­to­ read full press release/ article | Ref: Biomarin | Image: Fierce Biotech


Post Views:
2

Leave a Reply

Your email address will not be published. Required fields are marked *